https://www.selleckchem.com/pr....oducts/mizagliflozin
loping subsequent bacteremia. No significant differences were detected between groups receiving modified and non-modified treatments in duration of hospitalization or antibiotic therapy (univariate analysis) and 28-day mortality rate (logistic regression). Quinolone exposure was a major risk factor for ESBL-E and CRE fecal carriage. Performing rectal swab screening for MDR and modifying empirical antibiotic therapy accordingly did not improve clinical outcomes of febrile neutropenia patients. Quinolone exposure was a major risk fa
Like
Comment
Share
